组蛋白去乙酰化酶抑制剂专利分析  

Patent application analysis of histone deacetylase inhibitors

作　　者：王玮 薛建强 WANG Wei;XUE Jian-qiang(Guangzhou BaiYunShan Pharmaceutical Holdings Co.,Ltd.,Guangzhou BaiYunShan Pharmaceutical General Factory/Key Laboratory of Key Technology Research on Chemical Raw Materials and Preparations of Guangdong Province,Guangzhou 510515,China;Guangzhou Jiaquan Patent and Trademark Office Co.,Ltd.,Guangzhou 510627,China)

机构地区：[1]广州白云山医药集团股份有限公司白云山制药总厂,广东省化学药原料与制剂关键技术研究重点实验室,广州510515 [2]广州嘉权专利商标事务所有限公司,广州510627

出　　处：《中国新药杂志》2021年第12期1068-1072,共5页Chinese Journal of New Drugs

基　　金：广州市知识产权运营服务体系建设2019—2020年中央专项资金项目(穗市监知产促进合[2020]号);国企知识产权高质量发展项目(穗市监知促合[2021]7号)。

摘　　要：本文以INCOPAT数据库为基础,检索分析了组蛋白去乙酰化酶抑制剂(HDACIs)的专利情况,对该领域专利申请趋势、申请人国别、PCT申请、排名前10的申请人、国内专利申请人及其主要技术领域进行分析,以期为国内制药企业和研发机构开展HDACIs的新药研发及专利布局提供参考。The database of INCOPAT platform was used to search patent applications of histone deacetylases(HDACs),and the data was analyzed,including its development trends,global patent applicants,PCT applications,the top 10 applicants,domestic applicants and their technical fields etc.,aiming at providing references on new drug development and patent layout for domestic pharmaceutical enterprises,research and development institutions.

关 键 词：组蛋白去乙酰化酶抑制剂 专利分析 专利布局 

分 类 号：R95[医药卫生—药学]